Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 29, 2005 | Tamoxifen | FDA US | Malignant Breast Neoplasm | For treatment of adult patients with estrogen receptor-positive metastatic breast cancer | ORIGNDA021807 | approved | openfda |
| Oct 28, 2005 | Nelarabine | FDA US | cancer not stated in this record | ARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult… | ORIGNDA021877 | approved | openfda |
| Oct 20, 2005 | Imatinib Mesylate | FDA US | cancer not stated in this record | Efficacy supplement 2005-10-20 (see label) | SUPPLNDA021588 | approved | openfda |
| Oct 20, 2005 | Imatinib | FDA US | cancer not stated in this record | Efficacy supplement 2005-10-20 (see label) | SUPPLNDA021588 | approved | openfda |
| Oct 5, 2005 | Exemestane | FDA US | cancer not stated in this record | Efficacy supplement 2005-10-05 (see label) | SUPPLNDA020753 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 29, 2005 | Bevacizumab | FDA US | cancer not stated in this record | Efficacy supplement 2005-09-29 (see label) | SUPPLBLA125085 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 15, 2005 | Capecitabine | FDA US | cancer not stated in this record | Efficacy supplement 2005-06-15 (see label) | SUPPLNDA020896 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 13, 2005 | Peginterferon Alfa-2a | FDA US | cancer not stated in this record | Efficacy supplement 2005-05-13 (see label) | SUPPLBLA103964 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 25, 2005 | Bortezomib | FDA US | cancer not stated in this record | Efficacy supplement 2005-03-25 (see label) | SUPPLNDA021602 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 25, 2005 | Peginterferon Alfa-2a | FDA US | cancer not stated in this record | Efficacy supplement 2005-02-25 (see label) | SUPPLBLA103964 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 28, 2005 | Doxorubicin | FDA US | cancer not stated in this record | Efficacy supplement 2005-01-28 (see label) | SUPPLNDA050718 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 14, 2004 | Leuprolide | FDA US | Malignant Prostate Neoplasm | VABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated… | ORIG |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 19, 2004 | Sertraline | FDA US | cancer not stated in this record | Efficacy supplement 2004-08-19 (see label) | SUPPLNDA020990 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 24, 2004 | Irinotecan | FDA US | cancer not stated in this record | Efficacy supplement 2004-06-24 (see label) | SUPPLNDA020571 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 28, 2004 | Fludarabine | FDA US | Chronic Lymphocytic Leukemia | Fludarabine Phosphate Injection is a nucleotide metabolic inhibitor indicated for: The treatment of adult patients with B-cell chronic… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 26, 2004 | Interferon Beta-1a | FDA US | cancer not stated in this record | Efficacy supplement 2004-03-26 (see label) | SUPPLBLA103780 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 26, 2004 | Bevacizumab | FDA US | cancer not stated in this record | in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more… |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| Sep 16, 2005 | Anastrozole | FDA US | cancer not stated in this record | Efficacy supplement 2005-09-16 (see label) | SUPPLNDA020541 | approved | openfda |
| Sep 15, 2005 | Pegfilgrastim | FDA US | cancer not stated in this record | Efficacy supplement 2005-09-15 (see label) | SUPPLBLA125031 | approved | openfda |
| Jul 27, 2005 | Ibritumomab Tiuxetan | FDA US | cancer not stated in this record | Efficacy supplement 2005-07-27 (see label) | SUPPLBLA125019 | approved | openfda |
| Jun 3, 2005 | Metformin | FDA US | cancer not stated in this record | Metformin Hydrochloride Extended-Release Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults… | ORIGNDA021748 | approved | openfda |
| Mar 15, 2005 | Temozolomide | FDA US | cancer not stated in this record | Efficacy supplement 2005-03-15 (see label) | SUPPLNDA021029 | approved | openfda |
| Mar 14, 2005 | Imatinib Mesylate | FDA US | cancer not stated in this record | Efficacy supplement 2005-03-14 (see label) | SUPPLNDA021588 | approved | openfda |
| Mar 14, 2005 | Imatinib | FDA US | cancer not stated in this record | Efficacy supplement 2005-03-14 (see label) | SUPPLNDA021588 | approved | openfda |
| Mar 11, 2005 | Sirolimus | FDA US | cancer not stated in this record | Efficacy supplement 2005-03-11 (see label) | SUPPLNDA021083 | approved | openfda |
| Mar 11, 2005 | Sirolimus | FDA US | cancer not stated in this record | Efficacy supplement 2005-03-11 (see label) | SUPPLNDA021110 | approved | openfda |
| Mar 2, 2005 | Epirubicin | FDA US | cancer not stated in this record | Efficacy supplement 2005-03-02 (see label) | SUPPLNDA050778 | approved | openfda |
| Jan 7, 2005 | Paclitaxel | FDA US | Pancreatic Adenocarcinoma | Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. | ORIGNDA021660 | approved | openfda |
| Jan 7, 2005 | Paclitaxel | FDA US | Lung Non-Small Cell Carcinoma | Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who… | ORIGNDA021660 | approved | openfda |
| Jan 7, 2005 | Paclitaxel | FDA US | Malignant Breast Neoplasm | Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant… | ORIGNDA021660 | approved | openfda |
| approved |
| openfda |
| Dec 10, 2004 | Anagrelide | FDA US | cancer not stated in this record | Efficacy supplement 2004-12-10 (see label) | SUPPLNDA020333 | approved | openfda |
| Oct 27, 2004 | Doxorubicin | FDA US | cancer not stated in this record | Efficacy supplement 2004-10-27 (see label) | SUPPLNDA050718 | approved | openfda |
| Oct 22, 2004 | Ibritumomab Tiuxetan | FDA US | cancer not stated in this record | Efficacy supplement 2004-10-22 (see label) | SUPPLBLA125019 | approved | openfda |
| Aug 19, 2004 | Sertraline | FDA US | cancer not stated in this record | Efficacy supplement 2004-08-19 (see label) | SUPPLNDA019839 | approved | openfda |
| Aug 18, 2004 | Docetaxel | FDA US | cancer not stated in this record | Efficacy supplement 2004-08-18 (see label) | SUPPLNDA020449 | approved | openfda |
| Jun 1, 2004 | Meloxicam | FDA US | cancer not stated in this record | Osteoarthritis (OA) • Rheumatoid Arthritis (RA) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age or older | ORIGNDA021530 | approved | openfda |
| May 19, 2004 | Azacitidine | FDA US | cancer not stated in this record | Adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed… | ORIGNDA050794 | approved | openfda |
| May 19, 2004 | Azacitidine | FDA US | Juvenile Myelomonocytic Leukemia | Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML). | ORIGNDA050794 | approved | openfda |
| ORIGANDA076661 |
| approved |
| openfda |
| Mar 8, 2004 | Cinacalcet | FDA US | cancer not stated in this record | Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. • Hypercalcemia in adult patients with… | ORIGNDA021688 | approved | openfda |
| Mar 8, 2004 | Cinacalcet | FDA US | Parathyroid Carcinoma | Limitations of Use: Sensipar is not indicated for use in patients with CKD who are not on dialysis Hypercalcemia in adult patients with… | ORIGNDA021688 | approved | openfda |
| ORIGBLA125085 |
| approved |
| openfda |
| Feb 26, 2004 | Bevacizumab | FDA US | Hepatocellular Carcinoma | Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have… | ORIGBLA125085 | approved | openfda |
| Feb 26, 2004 | Bevacizumab | FDA US | Malignant Peritoneal Neoplasm | Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a… | ORIGBLA125085 | approved | openfda |
| Feb 26, 2004 | Bevacizumab | FDA US | Malignant Cervical Neoplasm | Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. | ORIGBLA125085 | approved | openfda |
| Feb 26, 2004 | Bevacizumab | FDA US | Renal Cell Carcinoma | Metastatic renal cell carcinoma in combination with interferon alfa. | ORIGBLA125085 | approved | openfda |
| Feb 26, 2004 | Bevacizumab | FDA US | Glioblastoma | Recurrent glioblastoma in adults. | ORIGBLA125085 | approved | openfda |
| Feb 26, 2004 | Bevacizumab | FDA US | Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and… | ORIGBLA125085 | approved | openfda |